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Abstract. The aim of this study was to evaluate the apoptotic
damage to bone marrow cells caused by three chemotherapy
regimens for advanced Hodgkin's lymphoma, ABVD,
COPPEBVCAD and BEACOPP, which were randomly
administered in the HD 2000 GISL trial. Bone marrow
mononuclear cells (BMMCs) stained with anti-CD34
antibody and Annexin V, were evaluated by flow cytometry
before starting chemotherapy, 30 days after completing
chemotherapy and after 6 months. Results are expressed as
the percentages of BMMCs positive to anti-CD34, to
Annexin V or to both. Fourteen patients treated with ABVD,
11 with COPPEBVCAD and 13 with BEACOPP were
evaluated before and 30 days after treatment. Late assess-
ments were made in 6, 7 and 8 of them, respectively. No
differences were found among the pretherapeutic flow
cytometry findings in relation to the staging characteristics
(marrow involvement included). All the regimens increased
the apoptotic fraction of the whole mononuclear bone marrow
cells (COPPEBVCAD did so significantly) and increased the
CD34+ compartment (with significant early differences after
ABVD and BEACOPP, tending to late persistence for ABVD,
only). All the regimens increased the apoptotic CD34+ cells
within the whole BMMC population (significantly after
BEACOPP), although with a general trend to decrease in
their percentage within the CD34+ compartment over time,
even after the most dose-dense regimens. Based on the
variations induced in the apoptotic fraction of all
mononuclear and CD34+ cells, ABVD was the least toxic
regimen and COPPEBVCAD the most toxic one.
Introduction
Combination chemotherapy has been the cornerstone of the
treatment of advanced Hodgkin's lymphoma for several
decades. Initial optimism generated from the dramatic results
achieved with mechlorethamine, vincristine, procarbazine,
and prednisolone (MOPP) was later tempered by two growing
realizations: first, that further improvements in clinical
results would be slow, of reduced impact, and hard-earned;
secondly, that despite prolonged remission and cure, serious
late effects of chemotherapy could be an intolerable counter-
balance of clinical results (1). So, when in 2000 the Gruppo
Italiano per lo Studio dei Linfomi (GISL) designed a ran-
domized trial comparing three different chemotherapy
regimens (2), it also planned, besides the mandatory record
of early and late side effects, some parallel investigations
aimed at an early and direct evaluation of the effects on the
stem cell compartment potentially responsible for persistent
marrow damage and the consequent defective ability to
mobilize progenitor cells.
Such damage might interfere with the feasibility of auto-
logous bone marrow transplantation (AuBMT), a procedure
that might be needed as part of the salvage treatment for
resistant or relapsing cases (3). Since the slow improvement
of clinical responses achieved over the last 20 years has been
reached through intensification of drug doses and resulting
toxicity, it is possible that a variable part of the improved
response produced by particularly intense and aggressive
chemotherapy might be paid for by a reduced possibility of
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rescue with transplantation procedures if these become
necessary. It might, therefore, be questioned whether it is
better to use a less myelotoxic, though not highly performing,
regimen which leaves a good possibility of AuBMT or to
achieve the maximum early clinical response even at the risk
of compromising the ability to mobilize adequate amounts of
stem cells in the case of resistance or relapse. In order to
investigate this issue, we assessed the grade of apoptosis
caused to BMMCs by three drug regimens currently used in
the treatment of patient with advanced-stage Hodgkin's
lymphoma: ABVD (4) (doxorubicin, bleomycin, vinblastine
and dacarbazine), COPPEBVCAD (a minimal variant of
MOPPEBVCAD (5) in which cyclophosphamide replaces
mechlorethamine and other drugs, vincristine, procarbazine,
prednisone, epidoxorubicin, bleomycin, vinblastine, lomustine,
melphalan and vindesine, remain unmodified) and BEACOPP
(6) (bleomycin, etoposide, doxorubicin, cyclophosphamide,
vincristine, procarbazine and prednisone). Apoptosis was
evaluated through the high affinity of Annexin V for phos-
phatidylserine, a cell membrane phospholipid which is early
exposed on the external surface at the beginning of the
apoptotic process.
Materials and methods
Patients and treatments. The population of the study was
an unselected sample of the larger series randomized in the
HD 2000 GISL multicenter trial between 2000 and 2006. In
this study treatment consisted of six courses of one of the
three multiple-drug chemotherapy regimens -ABVD,
COPPEBVCAD and BEACOPP- followed by optional
radiotherapy, which had to be delivered to no more than
two distinct areas corresponding to either bulky masses at
diagnosis or incompletely remitting lesions after chemotherapy.
The schedules of the randomized regimens are detailed in
Table I. The cumulative dose of radiotherapy had to be 30 Gy.
The proposed object was to study at least ten patients in
each of the randomization arms. Patients who gave their
written consent underwent bone marrow aspiration 1-3 days
before the start of chemotherapy (assessment 1), 30 days
after stopping chemotherapy (assessment 2) and 6 months
after the end of chemotherapy (assessment 3), irrespective of
whether the optional brief program of irradiation was delivered
after chemotherapy. The marrow samples were collected in
test-tubes, sealed in containers at a constant temperature and
sent by a quick courier service to reach the central evaluation
laboratory within no more than 24 h. The patients were
admitted to the study based simply on their willingness to
undergo the procedures and the agreement of their GISL
treatment center to co-operate in this study; some willing
patients from co-operating studies were, however, excluded
because of clinical or technical circumstances potentially
interfering with the collection or analysis of their samples
(for example, clinical conditions requiring immediate treat-
ment, proximity of bank holidays, casual temporary inability
of the central laboratory, accidental damage of the sample
during transport). In all, 14 patients treated with ABVD, 11
with COPPEBVCAD and 13 with BEACOPP underwent
assessments 1 and 2 while 6, 7 and 8, respectively had
assessment 3. There were no selection biases affecting the
three groups of patients, as demonstrated by the clinical
characteristics reported in Table II.
Samples. Fresh bone marrow was obtained from the posterior
superior iliac spine. Two milliliters of marrow were sampled
from the first vigorous aspiration into a heparinized syringe,
and put into a plastic test-tube with a watertight cap. The
samples were then sent, without delay and protected from
thermal shock, to the central laboratory where they under-
went cell death assays.
Cell death assays. BMMCs were isolated by density
gradient centrifugation over Ficoll-Paque (d=1.077 g/ml;
Pharmacia Biotech) and washed twice in phosphate-
buffered saline (PBS, Sigma). A total of 106 cells per sample
were used. Cells were incubated with phycoerythrin (PE)-
conjugated and anti-CD34 monoclonal antibody (Mab, Clone
8G12, Anti-HPCA-2, IgG1; Becton-Dickinson) for 20 min
at room temperature in the dark and then washed twice in
PBS. Pelleted cells were resuspended in 100 μl binding
buffer (10 mmol/l Hepes/NaOH, pH 7.4, 140 mmo/l NaCl,
2.5 mmo/l CaCl2; Bender Medsystems, Boehringer Ingelheim)
and incubated with 10 μl fluorescein isothiocyanate (FITC)-
conjugated Annexin V (Bender Medsystems, Boehringer
Ingelheim) for 10 min at room temperature in the dark.
Cells were then resuspended in 400 μl binding buffer prior to
flow cytometric analysis. Negative controls included MNC
incubated with neither CD34-PE Mab nor Annexin-V-FITC
and cells incubated with CD34-PE Mab only.
Two-color analysis of Annexin V within CD34+ cell
populations was performed using an EPICS XL flow cyto-
meter (Coulter). Data were obtained in list mode, acquiring
at least 2x106 events per sample and/or at least 104 events
within the CD34+ cell gate. The analysis of apoptosis was
based on gating subpopulations of CD34+ cells by forward
scatter vs. side scatter as well as side scatter vs. fluores-
cence 2. The percentage of apoptotic cells was determined by
comparing the fluorescence distribution histogram of
positively stained cells to that of cells to which no Annexin V
had been added (Fig. 1).
The following four evaluations were made on each
sample: per cent of BMMCs positive to FITC-Annexin V
(Ann+), including both myelopoietic and immunopoietic
component; per cent of BMMCs positive to CD34-PE Mab
(CD34+), which corresponds to the myelopoietic compart-
ment only; per cent of BMMCs positive to both CD34-PE
Mab and FITC-Annexin V (34+A+), wich gives information
about the death fraction among the myelopoietic cells related
to the whole BMMCs; per cent of all CD34+ cells that were
also positive to Annexin V (A+/34+), which reflects the death
fraction within the hemopoietic stem cells. This parameter
was considered to evaluate the apoptotic fraction of the
CD34+ cells independent of the contemporary possible
variation of apoptosis among the BMMCs.
Statistical analysis. Given that the data were not normally
distributed, comparisons were tested using Wilcoxon's rank
sum test and were performed among groups two by two (7).
The data are graphically represented in Figs. 1-4 by means of
box plots that show the 10th, 25th, 50th (i.e., the median), 75th
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Table I. Drug doses and time schedules of the three chemotherapy regimens investigated in the study.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Drug Dose (mg/m2) Route Days
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
ABVDa
Doxorubicin 25 i.v. 1.15
Bleomycin 5 i.v. 1.15
Vinblastine 6 i.v. 1 15
Dacarbazine 375 i.v. 1.15
COPPEBVCADa
Cyclophosphamide 650 i.v. 1 (cycles 1, 3 and 5, only)
Lomustine (CCNU) 100 p.o 1 (cycles 2, 4 and 6, only)
Vindesine 3 i.v. 1
Melphalan 6 p.o. 1-3
Prednisone 40 p.o. 1-14
Epidoxorubicin 40 i.v. 8
Vincristine 1.4 i.v. 8
Procarbazine 100 p.o. 8-14
Vinblastine 6 i.v. 15
Bleomycin 10 i.v. 15
BEACOPPb
Cyclophosphamide 650 (1200) i.v. 1
Doxorubicin 25 (35) i.v. 1
Etoposide 100 (200) i.v. 1-3
Procarbazine 100 p.o. 1-7
Vincristinec 1.4 i.v. 8
Bleomycin 10 i.v. 8
Prednisoned 40 p.o. 1-14
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
Six cycles were planned for all the regimens. aCycles were repeated every 28 days; day 29 was the start of a new cycle. bDoses outside
brackets refer to the baseline schedule, those inside brackets to the intensified version; cycles 1-4 were intensified, cycles 5-6 baseline;
cycles were repeated every 21 days, day 22 being start of a new cycle.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––




Number 14 11 13
Median age (and range) 36 (20-65) 33 (15-61) 36 (21-61)
Male/Female ratio 5/9 5/6 6/7
Stage IIB/III/IV 4/7/3 2/5/3 4/5/4
Histology: LD vs. others 2/12 3/8 3/10
Bulky mass 8 5 6
Hb (g/dl, mean ± SD) 11.8±1.7 11.0±1.8 11.4±2.1
Alb (g/l, mean ± SD) 3.9±0.7 3.8±0.5 3.6±0.7
LDH (mU/ml, mean ± SD) 487±227 416±231 481±282
WBC (109/l, mean ± SD) 10.3±5.2 12.7±6.1 11.4±5.4
Ly (109/l, mean ± SD) 1.5±0.8 2.2±1.2 1.7±1.0
Radiotherapy 7 5 6
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
LD, lymphocyte depletion; Hb, hemoglobin concentration; Alb, serum albumin concentration; LDH, serum lactate dehydrogenase
concentration; WBC, white blood cell count; Ly, blood lymphocyte count.
–––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––
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and 90th percentiles of data, with single values above the 90th
and below the 10th percentiles plotted as distinct points.
Results
No differences were found among the distribution of Ann+,
CD34+, 34+A+ and A+/34+ cells in relation to the main staging
characteristics (stage; constitutional symptoms; bulky
disease; histology; hemoglobin, serum albumin, and serum
lactate dehydrogenase concentrations; marrow involvement)
and to the treatment arms.
The proportion of apoptotic cells within the whole
population of BMMCs was not substantially increased after
either ABVD or BEACOPP treatment (Fig. 2), while there
was a clear rise after COPPEBVCAD, both early and late
after the end of therapy. Fig. 3 illustrates the percentage
variations of the CD34+ cells according to treatment arm.
There were increases in CD34+ cells early after all treat-
ments (significant in the ABVD arm), with a trend to higher
and significant  late values after both ABVD and BEACOPP.
The percentage of the cells simultaneously positive to
CD34-PE Mab and FITC-Annexin V (i.e., the apoptotic stem
cells) related to the whole BMMC compartment increased
after therapy, whichever regimen was administered (Fig. 4).
This increase was more evident earlier than later after all
treatments; the percentage of apoptotic stem cells was signi-
ficantly highest after BEACOPP treatment and less high after
the ABVD and COPPEBVCAD regimens.
Fig. 5 illustrates the variations of the apoptotic cell
fraction within the stem cell population. The percentages of
these Ann+ cells within the whole CD34+ compartment
tended to decrease after chemotherapy (i.e., the increase of
all the progenitor cells is higher than that of their apoptotic
quote) except for COPPEBVCAD, which showed persisting
higher percentages of apoptotic cells 30 days after the end of
treatment. Though these variations are not statistically
significant, the distribution of the data, and their median
values, provides some evidence of a more considerable and
progressive decrease after BEACOPP than after the other
regimens.
No substantial differences were found in the results of the
assays performed 6 months after chemotherapy according to
whether the patients had received radiotherapy or not.
Discussion
Apoptosis is the primary mechanism by which radiation and
most chemotherapeutic agents induce tumor cell death. This
effect is not selective, involving both normal and malignant
cells, and depends on whether each individual cell is committed
to apoptosis in response to chemotherapy and/or radiotherapy
(8). Radiotherapy has progressively disappeared from first-
line treatment for Hodgkin's lymphoma and multiple-drug
chemotherapy now plays the pivotal role in the management
of this disease, leaving irradiation only a selected, limited
and complementary function. Moreover, it is becoming clear
that in most cases, after failure of primary treatment, high-
dose chemotherapy followed by AuBMT is significantly more
effective than non-transplant salvage therapy, regardless of
whether the relapse occurs early or late after primary
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Figure 1. Flow cytometric evaluation of CD34+ cell apoptosis. Analysis was based on gating on CD34+ cell subpopulations side scatter (SSC) vs. fluorescence 2
(CD34PE) (a). Percentage of posivity was determined by comparison of the fluorescence distribution histogram (Annexin V FITC) of positively stained cells
(c) to that of cells to which no Annexin V was added (b).
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chemotherapy (3,9). Thus, it is likely that the choice of the
first-line chemotherapy should be guided not only by the
evidence of its efficacy and consideration of its potential late
toxicity, but also by whether it enables AuBMT procedures
should the first treatment fail.
For this reason we took the opportunity of studying
apoptosis of BMMCs in a limited number of the patients
enrolled in the GISL trial HD2000, which had the primary
end-point of comparing the efficacy and toxicity of three
distinct chemotherapy regimens, ABVD, COPPEBVCAD
and BEACOPP, in advanced Hodgkin's lymphoma. The basic
assumption regarding the aim of this work was that the treat-
ment inducing the lowest proportion of apoptosis of bone
marrow precursors might have a clinical advantage, efficacy
and toxicity being equal. It is questionable that the small
percentage of the additional early responses achievable with
more intensive and toxic chemotherapy may be paid for by
difficulty in harvesting bone marrow progenitor cells. In
light of this, it seems reasonable that a more complete and
correct assessment of the clinical value of a first-line regimen
should be coupled to a consideration of the feasibility and,
possibly, of the outcome of the planned rescue therapy in
the case of primary treatment failure, thus making a global
evaluation of the combined treatments. The attention to the
current parameters of response and toxicity of first-line treat-
ment alone should, therefore, be expanded to cover the whole
combination of first-line and salvage therapy which may
need to be offered. The GISL has now closed the recruitment
of patients into the HD2000 trial and the very preliminary
results have been communicated at the end of 2007 (2,10).
Herein, we present the results on direct, early and late
toxicity caused to the stem cell compartment by the three
treatment regimens used.
Some comments should be made regarding the results
obtained. The results are given as percentages of BMMCs,
since absolute counts are subject to a number of biases
(quantitative unreliability of any bone marrow aspirate
regarding the cell concentration which is actually present in
the marrow, together with potential minor technical
heterogeneity due to the multicenter basis of the investigation,
since it is hard to control for many differences in manual
procedures despite the strict instructions given regarding
power of aspiration, volume of marrow blood taken in the first
aspirate, heparin/blood ratio in the test-tubes). Thus, the
percentages given are related to a fixed number of BMMCs,
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Figure 2. Distribution of the percentages of all the apoptotic cells within the
whole bone marrow mononuclear population presented according to
chemotherapy arm, and analyzed before starting chemotherapy (1), and at 1
month (2) and 6 months after the end of chemotherapy. The horizontal lines
of the box plots show the 10th, 25th, 50th (i.e., the median), 75th and 90th
percentiles of the data, whereas single values above the 90th and below the
10th percentiles, if any, are plotted as distinct points. *Statistical differences
with P<0.05, #Statistical differences with P<0.01.
Figure 3. Distribution of the percentages of CD34+ cells within the marrow
mononuclear population presented according to chemotherapy arm, and
analyzed before starting chemotherapy (1), and at 1 month (2) and 6 months
(3) after the end of chemotherapy. Legends as in Fig. 1.
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irrespective of the exact amount of cells actually present in the
bone marrow.
The changes in the parameters observed 30 days after the
completion of chemotherapy were not biased by radiotherapy,
which, when given, was started after the second marrow
sample. Neither were the results obtained after 6 months
significantly affected by radiotherapy, since the median and
distribution of the data from patients who underwent radio-
therapy do not differ from those of subjects who did not
undergo this treatment. Moreover, the number of sites
exposed to radiotherapy, the irradiated volumes, and the
cumulative dosages were very limited, so that the influence
of radiotherapy on the whole bone marrow compartment
could have been expected to be minimal.
The 30-day interval from the end of chemotherapy and
the second assays was justified by the need to avoid variations
due to immediate toxicity and the consequent spontaneous
rapid marrow rescue. To this aim no growth factors were
given after the last cycle administered. So, the results at 30 days
should not reflect the stimulation induced either by the
temporary cytoreduction caused by chemotherapy or by the
administration of growth factors. Thus the assays do not
directly test the capacity for stem cell mobilization, although
it can be assumed that preserving a good amount of vital
stem cells is a necessary requirement for satisfactory mobili-
zation and harvesting of CD34+ cells for AuBMT.
ABVD seems to cause the most intense and prolonged
increase of the CD34+ cells, associated with the smallest
increase in the whole Ann+ BMMC compartment. The
apoptotic fraction of the CD34+ cells was not significantly
different 6 months after chemotherapy compared with pre-
treatment values.
COPPEBVCAD led to the lowest increase of CD34+ cells,
combined with the highest and constant rise of Ann+ BMMCs.
It can be argued that within this apoptotic compartment,
lymphocytes and monocytes increased more than CD34+ cells
so that the apoptotic proportion of the CD34+ cells showed a
modest non-significant increase after COPPEBVCAD, tending
to reduce in the subsequent 6 months.
BEACOPP caused a strong, temporary and statistically
significant rise of CD34+ cells in the first month, together
with a moderate, non-significant increase of the Ann+
compartment. Likely, and differently from COPPEBVCAD
which presents similar dose density (11), it exerted its toxic
effects more on the CD34+ compartment than on other
BMMCs and its entire apoptotic fraction significantly
increased in the first month, tending to pre-treatment levels
after 6 months.
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Figure 4. Percentages of the marrow mononuclear cells which are apoptotic
presented according to chemotherapy arm, and analyzed before starting
chemotherapy (1), and at 1 month (2) and 6 months after the end of
chemotherapy. Legends as in Fig. 1.
Figure 5. Distribution of the percentage apoptotic fraction of all the CD34+
marrow cells presented according to chemotherapy arm, and analyzed
before starting chemotherapy (1), and at 1 month (2) and 6 months (3) after
the end of chemotherapy. Legends as in Fig. 1.
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In conclusion, from the observed modifications of the
fractions of CD34+ cells and apoptotic cells within the whole
BMMC compartment, the ABVD regimen was the least toxic
to the bone marrow stem-cell component, while the
COPPEBVCAD regimen was the most toxic, causing a
generalized and prolonged increase of apoptosis, probably
also involving the immunocompetent cells among the MNC
population. The presence of alkylating agents and nitrosureas
in the COPPEBVCAD regimen might explain this effect.
BEACOPP showed an intermediate toxicity: the rise in
CD34+ cells that it caused was less prolonged than that
following treatment with ABVD, its stimulation of apoptosis
was less strong than that of COPPEBVCAD. One month
after BEACOPP the apoptotic cell fraction showed the
highest increase related to all BMMCs, but a modest decrease
within the CD34+ compartment, with a trend to a progressive
reduction over time, similar as that of the other regimens.
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